Predictors of 30-Day Survival in Patients With Nonpostcardiotomy Cardiogenic Shock Undergoing Combined Therapy with Venoarterial Extracorporeal Life Support and Microaxial Flow Pump

All articles of this category (opens in new window) Background: Venoarterial extracorporeal life support (VA-ECLS) combined with a microaxial flow pump (mAFP) for left ventricular (LV) unloading is an established treatment strategy to stabilize hemodynamics in patients with cardiogenic shock (CS). Methods: In a single-center retrospective study, 131 adults with nonpostcardiotomy CS treated with VA-ECLS and mAFP between February 2019 and September 2024 were analyzed. Primary outcomes were survival at 30 and 180 days. Secondary outcomes included LVEF, laboratory data, and temporary mechanical circulatory support (tMCS) details. Groups were compared regarding 30-day survival (Chi 2 , t -test, Mann–Whitney U test), and predictors were identified using univariable logistic regression and multivariable models. Results: Median age was 60 years [IQR: 52.5–65.5], and 18% were females. CS etiology was acute myocardial infarction in 45% and acute-on-chronic heart failure in 39%. Resuscitation before tMCS occurred in 55%. According to Kapur et al (2022), SCAI shock stage at tMCS implantation was C in 5%, D in 23% and E in 72%. Early tMCS implantation (